Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE: Duration of Immune Checkpoint Therapy in Urothelial Carcinoma
NCT04637594Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab in urothelial carcinoma (UC), sponsored by Cancer and Leukemia Group B. Started May 2022; status: active, not recruiting.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04637594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637594.